REG - Hutchmed China Ltd - Vesting of awards under the LTIP

HUTCHMED (China)Announcement

06/03/2023 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230306:nRSF9839Ra&default-theme=true

RNS Number : 9839R  Hutchmed (China) Limited  06 March 2023

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ - Monday, March 6, 2023: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM: HCM;
SEHK:13) announces that following the announcement of the 2022 annual results
of HUTCHMED on February 28, 2023, the following awards granted under the Long
Term Incentive Plan ("LTIP") on April 20, 2020 to Dr Weiguo Su and Mr Johnny
Cheng were vested on March 3, 2023:-

 

 Award Holders                                                                   Number of American depositary shares ("ADS")
 Person Discharging Managerial Responsibilities
 Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific  50,431
 Officer)
 Mr Johnny Cheng (Executive Director and Chief Financial Officer)                22,953


 Total                                                                           73,384

 

The notifications set out below are provided in accordance with the
requirements of the EU Market Abuse Regulation.

 

(a)  Dr Weiguo Su

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Dr Weiguo Su

 2    Reason for the notification

 a)   Position/status                                               Executive Director, Chief Executive Officer and Chief Scientific Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   ADS each representing five Ordinary Shares of US$0.10

      Identification code

                                                                    ADS ISIN: US44842L1035

 b)   Nature of the transaction                                     Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       50,431 ADS

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2023-03-03

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2023-03-03

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

(b)  Mr Johnny Cheng

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Mr Johnny Cheng

 2    Reason for the notification

 a)   Position/status                                               Executive Director and Chief Financial Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   ADS each representing five Ordinary Shares of US$0.10

      Identification code

                                                                    ADS ISIN: US44842L1035

 b)   Nature of the transaction                                     Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP

Price(s)  Volume(s)
 c)   Price(s) and volume(s)                                        Nil       22,953 ADS

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2023-03-03

 f)   Place of the transaction                                      Outside a trading venue

 

d)

 

Aggregated information

 -  Aggregated volume
 -  Price

 

N/A

 

e)

 

Date of the transaction

 

2023-03-03

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 
About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has about 5,000
personnel across all its companies, at the center of which is a team of about
1,800 in oncology/immunology. Since inception HUTCHMED has been focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President                  +852 2121 8200
 Annie Cheng, Vice President                      +1 (973) 306 4490

 Media Enquiries
 Americas - Brad Miles, Solebury Trout            +1 (917) 570 7340 (Mobile)

                                                  bmiles@soleburystrat.com (mailto:bmiles@soleburystrat.com)
 Europe - Ben Atwell / Alex Shaw, FTI Consulting  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                  +44 7779 545 055 (Mobile)   HUTCHMED@fticonsulting.com
                                                  (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                        +852 9783 6894 (Mobile)

                                                  HUTCHMED@brunswickgroup.com (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,                +44 (20) 7886 2500

Panmure Gordon (UK) Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHJFMRTMTIMMBJ